Loading…
Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.
Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.
Has no approved product, so it earns nothing from sales and pays for development by selling shares and other capital raises. Everything rests on RP1, an engineered herpes virus injected into tumours to kill cancer cells and prompt an immune response, studied alongside nivolumab in melanoma.
Moat: narrow (IP / patents, process know-how). Proprietary herpes-virus-based oncolytic platform engineered to boost anti-tumor immune response.
Headquarters: Woburn, Massachusetts, US · Founded: 2015 · Employees: 465
Size Replimune (REPL) is a United States Health Care company (Biotechnology) with a market value of $2.05B, the 1774th largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.62 on 6 Nov 2026.
Performance Over six months the shares gained 547.3%, against +20.0% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Short interest Short interest is 24.6% of the free float (15 Oct 2026).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$6.57M | -$6.53M | -$3.50M | -$2.65M | -$2.45M |
| EBITDA | -$265M | -$315M | -$260M | -$234M | -$178M |
| Net income | -$271M | -$314M | -$247M | -$216M | -$174M |
| Free cash flow | -$246M | -$285M | -$199M | -$191M | -$130M |
| Capital expenditure | $223,000 | $4.22M | $6.69M | $5.66M | $2.27M |
| Total debt | $127M | $112M | $76.2M | $75.9M | $60.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Replimune REPL | $2.05B | +547% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Candel Therapeutics CADL | $670M | +5% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REPL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +65.8% | +1.3% | highest of 21 |
| 6-month return | +547.3% | +20.0% | highest of 21 |
| Distance from 52-week high | -1.3% | -27.0% | highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% | +117.9% |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | 9.3× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $1.95B | +17% | +195% | -42% | 23.6× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |